Last reviewed · How we verify
Relapsed or refractory multiple myeloma
Approved treatments
- Pf-07284890 · Pfizer
- Pf-04171327 · Pfizer
PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM). - Bcmaxcd3 · Johnson & Johnson
Teclistamab-cqyv activates T-cells by binding to CD3 and BCMA, leading to the lysis of multiple myeloma cells. - Elrexfio · Pfizer
Bispecific antibody binding BCMA on myeloma cells and CD3 on T-cells, causing cytolysis. - Talvey · Janssen Biotech
Talquetamab binds to the T-cell surface glycoprotein CD3, triggering a response that kills cancer cells. - Pf-07985631 · Pfizer
- Lynozyfic · Rengeneron Pharmaceuticals, Inc.
Lynozyfic works by binding to specific cells involved in multiple myeloma. - Lynozyfic · Rengeneron Pharmaceuticals, Inc.
Lynozyfic works by binding to specific cells involved in multiple myeloma. - Elrexfio · Pfizer
Bispecific antibody binding BCMA on myeloma cells and CD3 on T-cells, causing cytolysis. - Elrantamab · Pfizer
- Pf-07248144 · Pfizer
- Melflufen · Oncopeptides AB
- Pf-07264660 · Pfizer
The mechanism of action of PF-07264660 is not specified. - Pf-07293893 · Pfizer
- TECVAYLI · JANSSEN BIOTECH
- TALVEY · JANSSEN BIOTECH
- Pf-07284892 · Pfizer
- Oral PF-07220060 · Pfizer
- Pf-08049820 Mr2 · Pfizer
- Pepaxto · Oncopeptides Ab
- Elrexfio · Pfizer
Elrexfio works by binding to tumor necrosis factor receptor superfamily member 17, a protein involved in the growth and survival of cancer cells.
Clinical guidelines
- FDA label — 4L+
ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. - FDA label — 3L+
ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. - FDA label — 3L+
ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Relapsed or refractory multiple myeloma patent landscape — cliff calendar, originator estates, attackable patents
- Relapsed or refractory multiple myeloma treatment landscape brief
- Relapsed or refractory multiple myeloma treatment updates RSS
Frequently asked questions about Relapsed or refractory multiple myeloma
What drugs treat Relapsed or refractory multiple myeloma?
Tracked treatments include Pf-07284890, Pf-04171327, Bcmaxcd3, Elrexfio, Talvey, Pf-07985631, Lynozyfic, Elrantamab.
What is the treatment for Relapsed or refractory multiple myeloma?
Standard treatment for Relapsed or refractory multiple myeloma includes Pf-07284890, Pf-04171327, Bcmaxcd3, Elrexfio, Talvey. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Relapsed or refractory multiple myeloma?
FDA label publishes guidelines for Relapsed or refractory multiple myeloma. 3 guideline references tracked.
Related
- Treatment landscape: Relapsed or refractory multiple myeloma patent cliff · Relapsed or refractory multiple myeloma CI report
- Treatment: Pf-07284890 · Pfizer
- Treatment: Pf-04171327 · Pfizer
- Treatment: Bcmaxcd3 · Johnson & Johnson
- Treatment: Elrexfio · Pfizer
- Treatment: Talvey · Janssen Biotech
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing